Sunshine Biopharma Inc. (SBFMW) stock
SBFMWNasdaqPharmaceutical PreparationsFiscal year ends December 31Also trades as SBFM
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 13, 2026Score 10/30
$0.03+0.00 (+2.00%)
Close on Oct 30, 2026Market cap $11.36MP/E –Yield –
Sunshine Biopharma operating income
Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.
Sunshine Biopharma's operating income for the twelve months ending Jun 30, 2026 was -$5.89M. For fiscal 2025 it was -$6.23M. The highest annual figure on record is -$556.20K in fiscal 2011.
Annual operating income
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$6.23M | – |
| FY2024 | Dec 31, 2024 | -$5.81M | – |
| FY2023 | Dec 31, 2023 | -$4.79M | – |
| FY2022 | Dec 31, 2022 | -$27.00M | – |
| FY2021 | Dec 31, 2021 | -$2.44M | – |
| FY2020 | Dec 31, 2020 | -$576.87K | – |
| FY2019 | Dec 31, 2019 | -$641.64K | – |
| FY2018 | Dec 31, 2018 | -$1.16M | – |
| FY2017 | Dec 31, 2017 | -$857.19K | – |
| FY2016 | Dec 31, 2016 | -$993.11K | – |
| FY2015 | Dec 31, 2015 | -$780.28K | – |
| FY2014 | Dec 31, 2014 | -$1.76M | – |
| FY2013 | Dec 31, 2013 | -$1.94M | – |
| FY2012 | Dec 31, 2012 | -$706.68K | – |
| FY2011 | Dec 31, 2011 | -$556.20K | – |
Quarterly operating income
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$1.61M | – |
| Q1 FY2026 | Mar 31, 2026 | -$1.40M | – |
| Q4 FY2025 | Dec 31, 2025 | -$1.79M | – |
| Q3 FY2025 | Sep 30, 2025 | -$1.09M | – |
| Q2 FY2025 | Jun 30, 2025 | -$2.05M | – |
| Q1 FY2025 | Mar 31, 2025 | -$1.30M | – |
| Q4 FY2024 | Dec 31, 2024 | -$2.04M | – |
| Q3 FY2024 | Sep 30, 2024 | -$1.11M | – |
| Q2 FY2024 | Jun 30, 2024 | -$1.27M | – |
| Q1 FY2024 | Mar 31, 2024 | -$1.35M | – |
| Q4 FY2023 | Dec 31, 2023 | -$1.19M | – |
| Q3 FY2023 | Sep 30, 2023 | -$779.47K | – |
| Q2 FY2023 | Jun 30, 2023 | -$1.01M | – |
| Q1 FY2023 | Mar 31, 2023 | -$1.83M | – |
| Q4 FY2022 | Dec 31, 2022 | -$23.36M | – |
| Q3 FY2022 | Sep 30, 2022 | -$1.72M | – |
| Q2 FY2022 | Jun 30, 2022 | -$695.80K | – |
| Q1 FY2022 | Mar 31, 2022 | -$1.22M | – |
| Q4 FY2021 | Dec 31, 2021 | -$279.63K | – |
| Q3 FY2021 | Sep 30, 2021 | -$496.26K | – |
| Q2 FY2021 | Jun 30, 2021 | -$388.60K | – |
| Q1 FY2021 | Mar 31, 2021 | -$1.28M | – |
| Q4 FY2020 | Dec 31, 2020 | -$343.32K | – |
| Q3 FY2020 | Sep 30, 2020 | -$67.29K | – |
| Q2 FY2020 | Jun 30, 2020 | -$128.57K | – |
| Q1 FY2020 | Mar 31, 2020 | -$37.70K | – |
| Q4 FY2019 | Dec 31, 2019 | -$250.59K | – |
| Q3 FY2019 | Sep 30, 2019 | -$202.64K | – |
| Q2 FY2019 | Jun 30, 2019 | -$66.20K | – |
| Q1 FY2019 | Mar 31, 2019 | -$122.21K | – |
| Q4 FY2018 | Dec 31, 2018 | -$143.71K | – |
| Q3 FY2018 | Sep 30, 2018 | -$288.83K | – |
| Q2 FY2018 | Jun 30, 2018 | -$580.51K | – |
| Q1 FY2018 | Mar 31, 2018 | -$166.70K | – |
| Q4 FY2017 | Dec 31, 2017 | -$162.18K | – |
| Q3 FY2017 | Sep 30, 2017 | -$113.81K | – |
| Q2 FY2017 | Jun 30, 2017 | -$472.22K | – |
| Q1 FY2017 | Mar 31, 2017 | -$108.99K | – |
| Q4 FY2016 | Dec 31, 2016 | -$336.10K | – |
| Q3 FY2016 | Sep 30, 2016 | -$116.02K | – |